MAFLD: Exploring the Systemic Effects Beyond Liver. DOI Creative Commons
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal

et al.

Journal of Community Hospital Internal Medicine Perspectives, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 4, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing global health concern which driven by the increasing prevalence of diabetes and obesity. MAFLD characterized excessive fat accumulation in liver, encompasses range conditions, from simple hepatic steatosis to more severe forms. This condition associated with various complications, including chronic kidney (CKD), Cardiovascular Disease (CVD), cirrhosis, even malignancy. Recent research has highlighted potential connection between gut dysbiosis MAFLD, particularly relation CKD. underscored significance gut-liver-kidney axis understanding MAFLD's pathogenesis. Inflammation triggered increases risk CVD through multiple mechanisms linked metabolic dysfunction. These include heightened oxidative stress, systemic insulin resistance, low-grade inflammation, endothelial Hepatic dysfunction are major diagnostic criteria for often coexisting other ailments. prospective review emphasizes intricate associations cardiovascular renal issues, diseases. Understanding underlying pathophysiological pathways crucial comprehending increased CKD, CVD, complications individuals MAFLD.

Language: Английский

The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus DOI
Xufen Zeng, Krista A Varady, Xiangdong Wang

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 161, P. 156028 - 156028

Published: Sept. 11, 2024

Language: Английский

Citations

25
Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Qingling Chen, Pingping Hu, Xiaoxue Hou

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: July 4, 2024

Abstract Background The prognostic value of triglyceride-glucose (TyG) related indices in non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic (MASLD) is still unclear. This study aimed to determine the associations between TyG-related and long-term mortality this population. Methods data came from National Health Nutrition Examination Survey (NHANES III) Death Index (NDI). Baseline TyG, TyG combining with body mass index (TyG-BMI), waist circumference (TyG-WC) were calculated, status was determined through 31 December 2019. Multivariate Cox restricted cubic spline (RCS) regression models performed evaluate relationship among participants NAFLD/MASLD. In addition, we examined association all-cause within subgroups defined by age, sex, race/ethnicity, fibrosis-4 (FIB-4). Results There 10,390 completed ultrasonography laboratory included study. NAFLD diagnosed 3672/10,390 (35.3%) participants, while MASLD 3556/10,390 (34.2%) amongst overall multivariate analyses showed high levels indices, particularly TyG-BMI TyG-WC significantly associated mortality, cardiovascular diabetes either MASLD. RCS curves a nonlinear trend three Subgroup that more suitable for predicting patients without advanced fibrosis. Conclusion Our highlights clinical survival NAFLD/MASLD would be surrogate biomarkers follow-up population

Language: Английский

Citations

22
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study DOI
Eugene Han, Byung‐Wan Lee, Eun Seok Kang

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 152, P. 155789 - 155789

Published: Jan. 13, 2024

Language: Английский

Citations

19
Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States DOI
Donghee Kim, Karn Wijarnpreecha, George Cholankeril

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 33 - 42

Published: April 22, 2024

Recently, a panel of multi-society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction-associated fatty (MAFLD) or nonalcoholic (NAFLD).

Language: Английский

Citations

18
MAFLD: Exploring the Systemic Effects Beyond Liver. DOI Creative Commons
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal

et al.

Journal of Community Hospital Internal Medicine Perspectives, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 4, 2025

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing global health concern which driven by the increasing prevalence of diabetes and obesity. MAFLD characterized excessive fat accumulation in liver, encompasses range conditions, from simple hepatic steatosis to more severe forms. This condition associated with various complications, including chronic kidney (CKD), Cardiovascular Disease (CVD), cirrhosis, even malignancy. Recent research has highlighted potential connection between gut dysbiosis MAFLD, particularly relation CKD. underscored significance gut-liver-kidney axis understanding MAFLD's pathogenesis. Inflammation triggered increases risk CVD through multiple mechanisms linked metabolic dysfunction. These include heightened oxidative stress, systemic insulin resistance, low-grade inflammation, endothelial Hepatic dysfunction are major diagnostic criteria for often coexisting other ailments. prospective review emphasizes intricate associations cardiovascular renal issues, diseases. Understanding underlying pathophysiological pathways crucial comprehending increased CKD, CVD, complications individuals MAFLD.

Language: Английский

Citations

4